NextCure (NASDAQ:NXTC) Stock Rating Lowered by Zacks Investment Research

NextCure (NASDAQ:NXTC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

According to Zacks, “NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company’s product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland. “

Several other analysts have also commented on NXTC. Morgan Stanley increased their price objective on NextCure from $25.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Piper Jaffray Companies reiterated a “positive” rating and set a $95.00 price objective (up previously from $54.00) on shares of NextCure in a report on Monday. Finally, Bank of America upped their target price on NextCure from $27.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, September 9th.

Shares of NXTC traded down $0.48 during midday trading on Tuesday, hitting $38.54. 14,004 shares of the company’s stock traded hands, compared to its average volume of 665,824. NextCure has a 1 year low of $13.86 and a 1 year high of $109.00. The company’s fifty day moving average is $35.08. The company has a current ratio of 17.05, a quick ratio of 17.05 and a debt-to-equity ratio of 0.02.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.15). The firm had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million. As a group, research analysts forecast that NextCure will post -1.8 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NXTC. Victory Capital Management Inc. acquired a new position in shares of NextCure in the 2nd quarter valued at $48,000. Tower Research Capital LLC TRC acquired a new position in shares of NextCure in the 2nd quarter valued at $96,000. Morgan Stanley acquired a new position in shares of NextCure in the 2nd quarter valued at $101,000. Strs Ohio increased its position in shares of NextCure by 625.0% in the 3rd quarter. Strs Ohio now owns 5,800 shares of the company’s stock valued at $178,000 after acquiring an additional 5,000 shares during the period. Finally, Northern Trust Corp acquired a new stake in NextCure during the 2nd quarter worth about $337,000. 47.19% of the stock is currently owned by hedge funds and other institutional investors.

NextCure Company Profile

There is no company description available for NextCure Inc

Recommended Story: Percentage Decliners

Get a free copy of the Zacks research report on NextCure (NXTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit